Le Lézard
Classified in: Health
Subject: SVY

Global $273 Bn Active Pharmaceutical Ingredient Market to 2026 Featuring TEVA Pharma & Dr. Reddys


DUBLIN, Feb. 14, 2019 /PRNewswire/ --

The "Global Active Pharmaceutical Ingredient Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The active pharmaceutical ingredient market was valued at US$ 152.6 Bn in 2017 and expected to reach US$ 273.5 Mn by 2026 at a CAGR of 6.7 % during the forecast period from 2018 to 2026.

The global active pharmaceutical ingredient (API) market shows fruitful growth during the forecast period from 2018 to 2026. The API is the active part of any drug that delivers its reaction. Many times a drug may contain few APIs and the reaction to a specific medication will rely upon the prescription of the dosage pattern, which changes from individual to individual. For instance, combination therapeutic treatments have various dynamic active ingredients to treat different side effects. TEVA Pharmaceuticals is one of the leading manufacturers of APIs in the global market having a vast portfolio of API products of around 300 APIs. Dr. Reddy's is also a leading API maker using more than 60 APIs currently.

North America to contribute maximum revenue share in the global active pharmaceutical ingredient market attributed to rising chronic diseases, higher adoption of prescribed drugs, demand for specialty drugs & biologics, increasing awareness, and rise in R&D for new drug formulations and development. In the current scenario, manufacturers present in the U.S. and Europe region are expanding their manufacturing capacity for APIs in the developing nations such as in India and China to cut expenses. This has made noteworthy changes in how these drugs are regulated, with more specific guidelines and regulations. For example, presently AstraZeneca Plc produce only 15% of their APIs in the U.S.

However, there are plans to end that small ratio and outsource all the manufacturing assembly in the Asia Pacific and Latin America market. Increase in healthcare spending is a global phenomenon, and this directly benefited the generics API market in recent years in the developing nations due to high demand and ease of access. However, the cost of enhancing process outline, higher cost of specialty API drugs, and stringent approvals regulations may act as a restraining factor to the overall development of the API market.

Improvement of new inventive API's and inorganic development through mergers and partnerships with smaller organizations additionally support the API market in the developing nations. Adoption of branded generic drugs & medications is growing exponentially in developing economies, for example, in India and China. In addition, rising utilization of specialty drugs expected to increase the pharmaceutical spending around the world.

Increase in demand for advanced therapeutics for treatment of alarming diseases, rising prevalence for chronic diseases and lifestyle diseases globally along with increasing purchasing power, beneficiary schemes for reimbursement are various factors fueling the demand for active pharmaceutical ingredient market in near future.

Key Market Movements:

Key Topics Covered:

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology

Chapter 2. Executive Summary
2.1. Global Active Pharmaceutical Ingredient Market Portraiture
2.2. Global Active Pharmaceutical Ingredient Market, By API Type, 2017 (US$ Mn)
2.3. Global Active Pharmaceutical Ingredient Market, By Drug Type, 2017 (US$ Mn)
2.4. Global Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2017 (US$ Mn)
2.5. Global Active Pharmaceutical Ingredient Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Active Pharmaceutical Ingredient Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Active Pharmaceutical Ingredient Technologies: Future Trends
3.3. Current Scenario: Strategies Used for Shifting Manufacturing Plants Internationally
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Active Pharmaceutical Ingredient Market, by API Type, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Synthetic Chemical API
4.3. Biological API

Chapter 5. Global Active Pharmaceutical Ingredient Market, by Drug Type, 2016 - 2026 (US$ Mn)
5.1. Overview
5.2. Branded Drugs
5.3. Generic Drugs
5.4. OTC Drugs

Chapter 6. Global Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 - 2026 (US$)
6.1. Overview
6.2. Contract Manufacturers
6.3. Captive Manufacturers

Chapter 7. Global Active Pharmaceutical Ingredient Market, by Geography, 2016 - 2026 (US$ Mn)

Chapter 8. Company Profiles
8.1. Teva Pharmaceutical Industries Ltd.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Pfizer, Inc.
8.3. Sanofi
8.4. Boehringer Ingelheim
8.5. Novartis International AG
8.6. Bristol-Myers Squibb
8.7. Eli Lilly and Company
8.8. GlaxoSmithKline plc
8.9. Merck & Co., Inc.
8.10. AbbVie Inc.
8.11. Lonza Group

For more information about this report visit https://www.researchandmarkets.com/research/rvfm5l/global_273_bn?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 03:05
August 22, 2019 Philips IntelliSite Pathology Solution adopted by Taiwan's leading academic medical and teaching center Taipei Veterans General HospitalPhilips IntelliSite Pathology Solution cleared for routine primary diagnostic use in Taiwan ...

at 03:00
TECH5 has successfully integrated MOSIP®1 with its T5-ABIS2 platform and Biometric SDKs for finger, iris and face recognition. TECH-5 presented a tested and ready-to-use solution with implemented biometrics to the Executive Committee and...

at 03:00
Daiichi Sankyo Company,...

at 03:00
- Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation...

at 02:55
Cantargia AB's ("Cantargia") half year report for the period January until June 2019 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant events in the second quarter  In May 2019, Cantargia AB and...

at 02:50
Iconic Therapeutics, a private biopharmaceutical company focused on novel therapeutics for serious diseases such as cancer and age-related macular degeneration (AMD), today announced that the Company has signed an agreement with Novartis (SIX:NOVN)...



News published on 14 february 2019 at 07:30 and distributed by: